AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01566019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumoral biopsy
Description: Every enrolled patient undergoes tumoral biopsy
Study NCT03421041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral Tablet
Description: Dexamethasone Oral Tablet，0.75mg/tablet
Study NCT03716531 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IORT
Description: IORT works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy
Study NCT01941888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT01941888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT02699385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
Study NCT01941888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion
Study NCT01418716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitation
Description: Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
Study NCT01418716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive diffusion
Description: Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
Study NCT03155737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure
Description: A training course will be offered to subjects in this group to train them to perform self-acupressure.
Study NCT03155737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee health education
Description: A course regarding knee health will be offered to the subjects in this group.
Study NCT00892788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Prize-based contingency management for weight loss
Study NCT00892788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight loss manual-guided individual therapy sessions
Description: once weekly counseling sessions with research staff
Study NCT00892788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss manual-guided individual therapy sessions
Description: once weekly counseling sessions with research staff
Study NCT00795496 — intervention group
Intervention type: PROCEDURE
Intervention: Histamine provocation
Description: A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
Study NCT00795496 — intervention group
Intervention type: PROCEDURE
Intervention: Skin prick tests
Description: Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
Study NCT00795496 — intervention group
Intervention type: PROCEDURE
Intervention: Serum IgE blood testing
Description: One blood test to measure total serum IgE
Study NCT00795496 — intervention group
Intervention type: PROCEDURE
Intervention: Mantoux-testing
Description: Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
Study NCT06240871 — intervention group
Intervention type: OTHER
Intervention: Pulmonary artery pressure measurements
Description: The investigators will compare noninvasive measurements of right sided pressure measurements with invasive RHC performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
Study NCT02363842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin IQ™ MCM Coverlet
Description: Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
Study NCT02699385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each participants will receive placebo oral suspension thrice daily for up to 7 days.
Study NCT04026594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences.
Study NCT04026594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation group
Description: control group
Study NCT01551355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children-Multicomponent intervention
Description: The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide.
Study NCT02024685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Treatment Recommendations
Description: This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
Study NCT02024685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard patient-physician counseling interaction
Description: Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
Study NCT02024685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard patient-physician counseling interaction
Description: Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
Study NCT03876210 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PK101
Description: PK101-001 + PK101-002 (combination)
Study NCT03876210 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PK101-001, PK101-002
Description: coadministration
Study NCT01976312 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
Study NCT01976312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
Study NCT01524952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combined thermal and electrical muscle stimulation (cTEMS)
Description: cTEMS in three 60-minute sessions per week for 8 weeks
Study NCT02971085 — intervention group
Intervention type: PROCEDURE
Intervention: Active surveillance
Description: Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
Study NCT02738320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHCPlus
Description: A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
Study NCT01291381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dermatophagoides pteronyssinus
Description: Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
Study NCT01291381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy
Description: For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
Study NCT02163252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Study NCT03581513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred or Immediate Stent Implantation
Description: IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.
Study NCT03581513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred or Immediate Stent Implantation
Description: IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.
Study NCT00943488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
Study NCT01346176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Directive Forms
Description: Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
Study NCT00914576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin and mineral supplement
Description: 1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
Study NCT02475395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRAK device
Description: Use of TRAK to attain sperm concentration measurement
Study NCT05877651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT-I injection
Description: The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
Study NCT02366754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
Study NCT02366754 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo rTMS
Description: The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
Study NCT00663455 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reduction of cyclosporine A (CSA)-dosing
Description: Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
Study NCT04379219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: giving methotrexate at least 1 w week before surgery
Study NCT02083926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
Study NCT02083926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline (a single 0.5mg/kg intravenously over 40 minutes).
Study NCT03614494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piroxicam 40 mg
Description: Additional co-treatment
Study NCT03614494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 1.5mg
Description: Standard treatment
Study NCT03614494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levonorgestrel 1.5mg
Description: Standard treatment
Study NCT05421104 — intervention group
Intervention type: OTHER
Intervention: Ruxolitinib
Description: PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
Study NCT02306057 — intervention group
Intervention type: PROCEDURE
Intervention: Pre BCPC
Description: Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
Study NCT02306057 — intervention group
Intervention type: PROCEDURE
Intervention: Pre TCPC
Description: Routine catheterization before surgical procedure Total CavoPulmonary Connection
Study NCT02306057 — intervention group
Intervention type: PROCEDURE
Intervention: BCPC surgery
Description: Surgical procedure Bidirectional CavoPulmonary Connection
Study NCT02306057 — intervention group
Intervention type: PROCEDURE
Intervention: TCPC
Description: Surgical procedure Total CavoPulmonary Connection
Study NCT01344382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement and Family Training
Description: The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
Study NCT01344382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Al-Anon Facilitation
Description: Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
Study NCT00766155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Given orally
Study NCT00766155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT00766155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT03313648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hepatectomy
Description: 180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
Study NCT03313648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: 180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
Study NCT00702208 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delphi Screener
Description: Self-sampling device for cervical vaginal lavage
Study NCT01842126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00010 IV
Description: Ascending Doses intravenous (IV) of BG00010
Study NCT01842126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00010 SC
Description: Ascending Doses subcutaneous (SC) of BG00010
Study NCT01842126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Ascending Doses intravenous (IV) of Placebo
Study NCT00914576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin and mineral supplement
Description: 1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
Study NCT01842126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Ascending Doses subcutaneous (SC) of placebo
Study NCT00914576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules/day for 14 days
Study NCT02163252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention
Study NCT01495624 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ropivacaine plus dexamethasone anesthetic
Description: Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
Study NCT01495624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine plus saline plus dexamethasone anesthetic
Description: Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
Study NCT00124878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Male circumcision
Description: Sleeve circumcision
Study NCT00124878 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Male circumcision
Description: Sleeve circumcision
Study NCT01616459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK2830929A
Description: Intramuscular injection
Study NCT01616459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK2830930A
Description: Intramuscular injection
Study NCT01616459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular injection
Study NCT01616459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Intramuscular injection
Study NCT01616459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa™
Description: Intramuscular injection
Study NCT01616459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular injection